Digital pathology in personalized cancer therapy

Folia Histochemica et Cytobiologica

Volumn 49, Issue 4, 2011, Pages 570-578

  Słodkowska, Janina ^a   Rojo, Marcial Garcia ^b  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

Author keywords

Breast cancer; Digital pathology; EGFR; HER 2; IHC biomarkers; Immunohistochemistry; NSCLC; Personalized targeted therapy; Quantitative analysis; Telepathology systems

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; CETUXIMAB; DACARBAZINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; GEFITINIB; K RAS PROTEIN; KI 67 ANTIGEN; PANITUMUMAB; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VEMURAFENIB;

APC GENE; BRAF GENE; BREAST CANCER; CANCER THERAPY; COLORECTAL CANCER; DIGITAL IMAGING; DIGITAL MICROSCOPY; EGFR GENE; GENE MUTATION; HER 2 GENE; HUMAN; IMMUNOHISTOCHEMISTRY; KRAS GENE; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MICROSCOPY; MOLECULAR PATHOLOGY; ONCOGENE; PERSONALIZED MEDICINE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

EID: 84856803150     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2011.0080     Document Type: Review

References (67)

1. Krenács T, Zsakovics I, Micsik T et al. Digital microscopy: the upcoming revolution in histopathology teaching, diagnostics, research and quality assurance. Microscopy: Science, Technology, Applications and Education. 2010;2:965-977. Ed: Antonio Méndez-Vilas and Jesús Díaz Álvarez. Publisher: Formatex Research Center, Vol 2 ISBN (13): 978-84-614-6190-5.
2. Weinstein RS, Graham AR, Richter LC et al. Overview of telepathology, virtual microscopy, and whole slide imaging: prospects for the future. Hum Pathol. 2009;40:1057-1069.
3. Rojo MG, García GB, Mateos CP, García JG, Vicente MC. Critical comparison of 31 commercially available digital slide systems in pathology. Int J Surg Pathol. 2006;4:285-305.
4. Rojo MG, Bueno G, Slodkowska J. Review of imaging solutions for integrated quantitative immunohistochemistry in pathology daily practice. Folia Histochem Cytobiol. 2009; 47:349-354.
5. http://www.aperio.com.
6. http://telepathology.upmc.edu/imitstelepathology/PDF/2007/DAKO%20APIII.pdf.
7. http://www.3dhistech.com/en/node/poducts-software.
8. S.976: Genomics and Personalized Medicine Act of 2007. United States Congress, Washington DC, USA. 2007.
9. Mok TS, Zhou Q, Leung L, Loong HH: Personalized medicine for non-small-cell lung cancer. Expert Rev Anticancer Ther. 2010;10:1601-1611.
10. Kalyuzhny AE. The dark side of the immunohistochemical moon: industry. J Histochem Cytochem. 2009;57:333-340.
11. Di Napoli A, Signoretti S. Tissue biomarkers in renal cell carcinoma: issues and solutions. Cancer. 2009;115(10 Suppl): 2290-2297.
12. López C, Lejeune M, Escrivà P et al. Effects of image compression on automatic count of immunohistochemically stained nuclei in digital images. J Am Med Inform Assoc. 2008; 15:794-798.
13. Cregger M, Berger AJ, Rimm DL. Immunohistochemistry and quantitative analysis of protein expression. Arch Pathol Lab Med. 2006;130:1026-1030.
14. Idikio HA. Contributions of protein life-cycle, use of evidencebased methods and data normalization on interpretation of immunohistochemical stains. Int J Clin Exp Pathol. 2010;3:169-176.
15. Camp RI, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol. 2008;26:5630-5637.
16. Rubin MA, Zerkowski MP, Camp RL et al. Quantitative determination of expression of the prostate cancer protein alpha- methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements. Am J Pathol. 2004;164:831-840.
17. Dhir R. Tissue microarrays: an overview. Methods Mol Biol. 2008;441:91-103.
18. Wang C-W. Robust automated tumour segmentation on histological and immunohistochemical tissue images. PLoS ONE. 2011; 6:e15818; doi:10.1371/journal.pone.0015818.
19. Taylor CR, Levenson RM. Quantification of immunohistochemistry - issues concerning methods, utility and semiquantitative assessment II. Histopathology. 2006;49:411-424.
20. Yaziji H, Taylor CR, Goldstein NS et al. Consensus recommendations on estrogen receptor testing in breast cancer by immunohistochemistry. Appl Immunohistochem Mol Morphol. 2008;16:513-520.
21. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784-2795.
22. Keedy VL, Temin S, Somerfield MR et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2011;29; http://jco.ascopubs.org/cgi/doi//10.1200/JCO.2010.31.8923.
23. Wolff AC, Hammond EH, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. J Clin Oncol. 2007;1:118-1145.
24. Cheng L, Zhang S, Alexander R et al. The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. Future Oncology. 2011;7:519-541.
25. Atkins D, Reiffen K-A, Tegtmeier CL et al. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining. Intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem. 2004;52:893-901.
26. Ludwig J, Weinstein J. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5: 845-856.
27. Dalton W, Friend S. Cancer biomarkers - an invitation to the table. Science. 2006;312:1165-1168.
28. Nakhleh RE, Grimm EE, Idowu MO, Souers RJ, Fitzgibbons PL. Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) Guidelines for Human Epidermal Growth Factor Receptor 2 (HER2) testing: a College of American Pathologists survey of 757 laboratories. Arch Pathol Lab Med. 2010;134:728-734.
29. Fitzgibbons PL, Murphy DA, Hammond ME, Allred DC, Paul N, Valenstein PN. Recommendations for validating estrogen and progesterone receptor immunohistochemistry assays. Arch Pathol Lab Med. 2010;134:930-935.
30. Sauter G, Lee J, Bartlett JMS, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27:1323-1333.
31. Ciampa A, Xu B, Ayata G et al. HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system. Appl Immunohistochem Mol Morphol. 2006;14:132-137.
32. Minot DM, Kipp BR, Root RM et al. Automated cellular imaging system III for assessing HER2 status in breast cancer specimens. Development of a standardized scoring method that correlates with FISH. Am J Clin Pathol. 2009;132: 133-138.
33. Cantaloni C, Tonini R E, Eccher C et al. Diagnostic value of automated Her2 evaluation in breast cancer: a study on 272 equivocal (score 2+) Her2 immunoreactive cases using an FDA approved system. Appl Immunohistochem Mol Morphol. 2011;19:306-312.
34. Słodkowska J, Violetta Filas V, Buszkiewicz E et al. Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio). Folia Histochem Cytobiol. 2010;48:19-25.
35. Lin NU, Winer EP. New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res. 2004;6:204-210.
36. Atalay G, Cardoso F, Awada A et al. Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol. 2003;14:1346-1363.
37. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-2743.
38. Vogel UF. Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization. Diagnostic Pathology. 2010;5:50; doi:10.1186/1746-1596-5-50.
39. Allred AC. Problems and solutions in the evaluation of hormone receptors in breast cancer J Clin Oncol. 2008;26:2433-2435.
40. Sharangpani GM, Joshi AS, Porter K et al. Semi-automated imaging system to quantitate estrogren and progesterone receptor immunoreactivity in human breast cancer. J Microscopy. 2007;226:244-255.
41. Rexhepaj E, Brennan DJ, Holloway P et al. Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer. Breast Cancer Res. 2008;10:R89.
42. Gokhale S, Rosen D, Sneige N et al. Assessment of two automated imaging systems in evaluating estrogen receptor status in breast carcinoma. Appl Immunohistochem Mol Morphol. 2007;15:451-455.
43. Tawfik OW, Kimler BF, Davis M et al. Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. Histopathology. 2006;48:258-267.
44. Li AR, Chitale D, Riely GJ et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn. 2008;10:242-248.
45. Marchetti A, Martelle C, Felicioni L et al. EGFR mutations in non-small cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005;23:857-865.
46. Sakuma Y, Matsukuma S, Yoshihara M et al. Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas. Confirmation of the correlations with histologic subtypes and gene mutations. Am J Clin Pathol. 2007;128:100-108.
47. Motoi N, Szoke J, Riely GJ et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008;32:810-827.
48. Ohtsuka K, Ohnishi H, Fujiwara M et al. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component. Cancer. 2007;109:741-50.
49. Dacic S, Flanagan M, Cieply K et al. Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma. Am J Clin Path. 2006;125:860-865.
50. Gupta R, Dastane AM, Forozan F et al. Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method. Modern Pathology. 2009;22:128-133.
51. Hirsch FR, Varella-Garcia M, Bunn Jr PA et al. Epidermal growth factor receptor in non-small-cell lung carcinomas. Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21:3798-3807.
52. Chung KY, Shia J, Kemeny NE et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005;23:1803-1810.
53. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors - impact on future treatment strategies. Nat Rev Clin Oncol. 2010;7:493-507.
54. Yu J, Kane S, Wu J et al. Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res. 2009;15:3023-3028.
55. Russo A, Bazan V, Agnese V et al. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol. 2005;16 (Suppl 4):iv44-iv49.
56. Liu X, Jakubowski M, Hunt JL. KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis. Am J Clin Pathol. 2011;135:245-252.
57. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359:1757-1765.
58. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.
59. Steven M, Anderson SM. Laboratory methods for KRAS mutation analysis. Expert Rev Mol Diagn. 2011;11:635-642.
60. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27:2091-2096.
61. Quyn AJ, Steele RJ, Carey FA, Näthke IS. Prognostic and therapeutic implications of APC mutations in colorectal cancer. Surgeon. 2008;6:350-356.
62. Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol. 2000;18:1967-1979.
63. Kaz AM, Brentnall TA. Genetic testing for colon cancer. Nat Clin Pract Gastroenterol Hepatol. 2006;3:670-679.
64. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809-819.
65. Flaherty K, Puzanov I, Sosman J et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol (Meeting Abstracts). 2009;27:9000.
66. Rubinstein JC, Sznol M, Pavlick AC et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med. 2010;8:67;doi:10.1186/ /1479-5876-8-67.
67. Chapman PB, Hauschild A, Robert C et al. BRIM-3 Study Group: improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.